drugset / Trial / NCT00212316
Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)
Phase 2
Completed
60 enrolled
University of Rochester
Columbia University · collabHP Therapeutics Foundation · collabJohns Hopkins University · collabMassachusetts General Hospital · collabUniversity of Alabama at Birmingham · collabUniversity of California, San Diego · collabUniversity of Iowa · collabUniversity of Kansas · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and clinical impact of 15-grams daily of sodium phenylbutyrate (phenylbutyrate) in Huntington's disease and to lay the groundwork for possible subsequent trials designed to specifically address its ability to slow or halt the progression of the disease.
Timeline
- Start
- 2005-08
- Primary completion
- —
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sodium Phenylbutyrate | Small molecule | 15 g | Oral |